FDA Inspection 1224373 — Rubicon Research Canada Limited
The FDA completed an inspection of Rubicon Research Canada Limited on November 3, 2023 in Concord. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 3, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Concord (Canada)